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The role of cytokines in regulation of hemato-
poietic stem cells (HSCs) remains poorly under-
stood. Herein we demonstrate that thrombo-
poietin (THPO) and its receptor, MPL, are
critically involved in postnatal steady-stateHSC
maintenance, reflected in a 150-fold reduction
ofHSCs in adultThpo/mice. Further,whereas
THPO and MPL proved not required for fetal
HSC expansion, HSC expansion posttransplan-
tation was highly MPL and THPO dependent.
The distinct role of THPO in postnatal HSC
maintenance is accompanied by accelerated
HSC cell-cycle kinetics in Thpo/ mice and
reduced expression of the cyclin-dependent
kinase inhibitors p57Kip2 and p19INK4D as well
as multiple Hox transcription factors. Although
also predicted to be an HSC viability factor,
BCL2 failed to rescue the HSC deficiency of
Thpo/mice. Thus, THPO regulates posttrans-
plantation HSC expansion as well as the main-
tenance of adult quiescent HSCs, of critical im-
portance to avoid postnatal HSC exhaustion.
INTRODUCTION
A compartment of rare pluripotent hematopoietic stem
cells (HSCs) is both required and sufficient to sustain blood
cell production for life. The ability of HSCs to self-renew is
a requisite for their extensive expansion during fetal devel-
opment and posttransplantation (Iscove and Nawa, 1997;
Pawliuk et al., 1996) aswell as to sustain HSCs at relatively
constant numbers in adult bone marrow (BM) (Morrison
et al., 1996). Postnatal HSCself-renewal is closely coupled
to the cells’ unique cell-cycle kinetics. Although cycling
with very slow kinetics, adult HSCs are predominantly qui-Cellescent (Bradford et al., 1997; Cheshier et al., 1999), and it
is likely that maintenance of HSC quiescence and slow
cell-cycle progression could be critically involved in sus-
taining a self-renewing HSC compartment for life.
Our knowledge about physiological intrinsic and extrin-
sic cues regulating HSC maintenance and expansion
remains limited (Molofsky et al., 2004; Oostendorp et al.,
1999; Sauvageau et al., 2004; Wilson and Trumpp, 2006).
Notably, of the few essential intrinsic regulators of HSC
maintenance identified, PTEN and GFI-1 have been found
at least in part to act through restriction of HSC prolifera-
tion (Hock et al., 2004; Yilmaz et al., 2006b), as has the
cyclin-dependent kinase (CDK) inhibitor p21Cip1 (Cheng
et al., 2000b). Similarly, angiopoietin-1 has been identified
as an extrinsic regulator of HSC quiescence (Arai et al.,
2004). In striking contrast, a number of classical hemato-
poietic cytokines have, largely based on in vitro findings,
been suggested to rather act as potent stimulators of HSC
proliferation (Sauvageau et al., 2004; Zhu and Emerson,
2002). However, with the exception of thrombopoietin
(THPO), efforts to confirm their proposed roles as physio-
logical regulators of HSC maintenance and expansion
have failed (Sauvageau et al., 2004; Sorrentino, 2004), as
have extensive attempts to use combinations of cytokines
as proliferative factors to expand HSCs ex vivo (Oosten-
dorp et al., 1999).
Adult mice deficient in the genes encoding the hemato-
poietin cytokine Thpo or its receptor,Mpl, have been sug-
gested to have reduced HSC function and numbers
(Buza-Vidas et al., 2006; Kimura et al., 1998; Solar et al.,
1998), but the extent of this deficiency and themechanism
of action remain unexplored. Based on in vitro studies,
THPO has been proposed to be a potent stimulator of
HSC proliferation when acting in synergy with other cyto-
kines (Sitnicka et al., 1996). However, most cytokines syn-
ergizing with THPO to enhance proliferation, unlike THPO,
do not appear to play a physiological role in HSC mainte-
nance or expansion, and efforts to expand HSCs ex vivo
through such cytokine combinations have largely failed
(Oostendorp et al., 1999).When acting alone, THPOappearsStem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 671
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riched HSCs (Borge et al., 1996), and in agreement with
this, Mpl is most highly expressed in quiescent long-
term (LT)-HSCs rather than more rapidly cycling short-
term (ST)-HSCs and multipotent progenitors (MPPs)
(Buza-Vidas et al., 2006). Thus, rather than promoting
HSC cycling, THPO might play a crucial role in mainte-
nance of quiescent HSCs, either acting as an antiapop-
totic factor, as has been suggested for several other cyto-
kines (Cross and Dexter, 1991; Maraskovsky et al., 1997),
or potentially through sustaining adult HSC quiescence.
Importantly it would be predicted, if critically involved in
regulation of HSC quiescence, that Thpo/ mice might
not have an HSC deficiency in fetal development when
HSCs cycle rapidly and undergo extensive expansion
(Pawliuk et al., 1996) but that they postnatally would de-
velop a progressive HSC deficiency, as HSCs normally
would acquire a more quiescent phenotype. Investigation
of this would be of considerable relevance for regulation of
human HSCs, as patients with congenital amegakaryo-
cytic thrombocytopenia (CAMT), who are born with lack-
of-function mutations in Mpl, with exception to thrombo-
cytopenia appear to be born with normal hematopoiesis
but within few years develop a multilineage BM failure
(Ballmaier et al., 2003).
Here we investigated the dynamics of HSC expansion
and maintenance in Thpo/ mice and demonstrate that
THPO and its receptor MPL are essential for postnatal
HSC maintenance, but not for fetal HSC expansion, as
both Thpo/ and Mpl/ fetal livers (FLs) in fact rather
have slightly increasedHSCnumbers. In contrast,Thpo/
miceprogressively loseHSCnumberswithage, resulting in
amore than150-fold reduction in 1-year-oldmice, translat-
ing into slightly reduced BM cellularity and a multilineage
hematopoietic defect, less extensive but similar to what
is observed in CAMT patients (Ballmaier et al., 2003). This
critical role of THPO in postnatal HSC maintenance does
not appear to primarily reflect the proposed antiapoptotic
effects of THPO, as overexpression of BCL2 failed to
correct the HSC phenotype of Thpo/mice. Rather, line-
age (LIN)SCA1hiKIThi (LSK) CD34FLT3 cells in Thpo/
mice display accelerated cell-cycle kinetics and reduced
transcriptional expression of the negative cell-cycle regu-
lators p57Kip2 and p19INK4D and different Homeobox (Hox)
transcription factors. Additionally, we also found that HSC
expansion posttransplantation is highly THPO dependent,
implicating a distinct role of THPO in postnatal rather than
fetal HSC expansion. Thus, the cytokine THPO is a critical
regulator of postnatal maintenance of quiescent HSCs and
posttransplantation HSC expansion.
RESULTS
Expansion of Fetal HSCs in Thpo/ Mice
Whereas previous studies have implicated an important
role of THPO in regulation of adult multipotent stem/pro-
genitor cells (Buza-Vidas et al., 2006; Kimura et al., 1998;
Solar et al., 1998), its role in the extensive HSC expansion672 Cell Stem Cell 1, 671–684, December 2007 ª2007 Elsevieobserved during fetal development (Pawliuk et al., 1996)
had not been investigated. Surprisingly, we found embry-
onic day (E)14.5 FL cellularity to be significantly and repro-
ducibly increased in Thpo/mice (Figure 1A). Further, as
the frequencies of LSKFLT3 HSCs and LSKFLT3+ MPPs
were similar inwild-type (WT) and Thpo/ FLs (Figure 1B),
their absolute numberswere in fact slightly but significantly
enhanced inThpo/FLs (Figure 1C). Importantly, a similar
increase in FL cellularity (Figure 1E) and trend toward
elevated LSKFLT3 and LSKFLT3+ cells (Figures 1F–1G)
was observed inMpl/mice.
As self-renewing LT-HSCs can only be identified through
their unique ability to sustain multilineage hematopoiesis
in vivo (Iscove and Nawa, 1997), limiting numbers (2 3
104/mouse) of unfractionated E14.5 FL cells (CD45.2)
fromWTor Thpo/micewere transplanted intomyeloab-
lated recipients in competition with 2 3 105 WT BM cells
(CD45.1). In agreement with the phenotypic analysis,
a similar frequency of recipients of WT (25/34; 73%) and
Thpo/ (23/35; 65%) FL cells were positive for donor-de-
rived long-term peripheral blood (PB) multilineage (B, T,
and myeloid) reconstitution (Figure 1D). Combined with
the enhanced FL cellularity, these data further substanti-
ated the conclusion that THPO and MPL are not required
to promote and in fact if anything rather appear to some-
what restrict fetal HSC expansion.
Selective and Age-Progressive Loss
of Thpo/ HSCs
We next investigated the role of THPO in postnatal BM
HSC maintenance. Unlike in FL, the total number of BM
mononucleated cells in 2-week-old Thpo/ mice was
equivalent to that in WT mice (Figure 2A), whereas the
frequencies of LSKFLT3 HSCs and LSKFLT3+ MPPs
(Adolfsson et al., 2005) were clearly reduced (4.0-fold
and 2.7-fold, respectively). This demonstrates a distinctly
different role of THPO in regulation of fetal and early post-
natal HSCs.
We further investigated adult WT and Thpo/ mice
for phenotypically defined LSKCD34FLT3 LT-HSCs,
LSKCD34+FLT3 ST-HSCs, and LSKCD34+FLT3+ MPPs
(Adolfsson et al., 2005; Yang et al., 2005) (Figure 2B). At
3 months of age, LSKCD34FLT3 and LSKCD34+FLT3
cells were further reduced in Thpo/ mice by as
much as 7.9-fold and 7.5-fold, respectively, whereas
LSKCD34+FLT3+ cells were less reduced (3.5-fold).
When using CD150 as an additional and documented
marker for phenotypic identification of HSCs (Kiel et al.,
2005; Yilmaz et al., 2006a), a 16-fold reduction in
LSKCD34FLT3CD150+ cells was observed in 3-month-
old Thpo/ mice (Figure S1A in the Supplemental Data
available with this article online), and a similar (12-fold)
reduction of LSKCD150+ cells was observed in 3-month-
old Mpl/ mice (Figure 2C). In 1-year-old mice, the fre-
quencies of LSKCD34FLT3 and LSKCD34+FLT3 cells
were further reduced (14.5-fold and 9.1-fold, respectively),
whereas the reduction in LSKCD34+FLT3+ cells was
similar to that seen at 3 months (2.3-fold reduction; Fig-
ure 2B). Thus, whereas 57.6% of LSK cells are FLT3 inr Inc.
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THPO Maintains Quiescent HSCsFigure 1. Increased Numbers of Fetal Liver HSCs in Thpo/ and Mpl/ Mice
(A) Total nucleated cells in Thpo/ E14.5 FL (mean ± SD).
(B) Representative FACS plots of LSK analysis of E14.5 FL inWT and Thpo/mice. The panels show cells already gated as LIN and subsequently as
LSK and then FLT3 and FLT3+ subsets (LSKFLT3, LSKFLT3+). Numbers shown aremean percentages of total cells in 15–17mice of each genotype.
(C) Number of LSKFLT3 and LSKFLT3 cells in WT and Thpo/ E14.5 FL (mean ± SD).
(D) Total donor PB reconstitution (left) and donor-derived myeloid cells (right) in myeloablated WT recipients (CD45.1 or CD45.1/2) at 16 weeks after
transplantation of limiting doses (23 104 cells/mouse) of WT or Thpo/ E14.5 FL cells (CD45.2) in competition with 1–23 105 WT (CD45.1) BM cells
from 10-week-old mice. Each symbol represents an individual recipient, and horizontal bars indicate mean values of reconstitution in positive mice.
The numbers shown in the panels are the fraction of mice positive for lympho-myeloid reconstitution, using the threshold level of 0.1% total cells
(dashed line, left) and of 0.02% each of the B, T, and myeloid lineages (dashed line, right). Data shown are from two independent experiments.
(E) Total nucleated cells in Mpl/ E14.5 FLs (mean ± SEM).
(F) Representative FACS plots of LSK analysis of E14.5 FL in WT and Mpl/ mice.
(G) Numbers (mean ± SEM) of LSKFLT3 and LSKFLT3+ cells in WT and Mpl/ E14.5 FL.
All data in (E)–(G) represent mean values of eight mice analyzed of each genotype.1-year-old WT mice, only 23.6% have this phenotype in
Thpo/mice. This demonstrates a selective role of THPO
in maintenance of adult LT- and ST-HSCs with less effectCell Son MPPs, consistent with the high expression of MPL
and THPO responsiveness in HSCs and downregulation
in LSKCD34+FLT3hi MPPs (Buza-Vidas et al., 2006).tem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 673
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THPO Maintains Quiescent HSCsFigure 2. Selective and Progressive Postnatal Reduction of LT-HSCs in Thpo/ Mice
(A) Total nucleated BM cells (mean ± SD) from two tibias and two femurs and representative FACS plots of LSK subsets (LSKCD34FLT3,
LSKCD34+FLT3, and LSKCD34+FLT3+) from 2 week, 3 month (12–14 week), and 1-year-old WT and Thpo/mice. Numbers shown are mean per-
centages of total cells in 5–12 mice of each genotype (2 week, n = 12; 3 month, n = 5; and 1 year, n = 5).
(B) Mean (±SD) numbers of LSKCD34FLT3, LSKCD34+FLT3, and LSKCD34+FLT3+ cells in BM of 3month (n = 5–6), and 1 year (n = 5) old Thpo/
mice relative to age-matched WT controls.
(C) Mean (±SEM) numbers of LSK and LSKCD150+ cells in BM (two femurs and two tibias) of 3-month-oldWT andMpl/mice (n = 6), analyzed in two
separate experiments.
(D) Total donor-derived PB reconstitution and donor-derived myeloid contribution 16 weeks after transplantation of limiting doses (2 3 104 WT or
8 3 104 Thpo/ BM cells) from 3-month-old mice. Each circle represents an individual recipient, and horizontal bars indicate mean levels of recon-
stitution among positive mice. Frequencies shown are the fraction of mice positive for lympho-myeloid reconstitution, using the threshold level of
0.1% total cells (dashed line, left) and of 0.02% each of the B, T, and myeloid lineages (dashed line, right). Data shown are from two independent
experiments.674 Cell Stem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc.
Cell Stem Cell
THPO Maintains Quiescent HSCsTo evaluate the frequencies of functionally defined LT-
HSCs in 3-month-old WT and Thpo-deficient mice, a lim-
ited dose of BM cells fromWT or Thpo/mice was trans-
planted competitively into myeloablated WT recipients
(for experimental design, see Figure S2). Based on the
frequency of recipient mice positive for donor-derived
long-term multilineage reconstitution (Figure 2D), a 40-
fold reduction of LT-HSCs in Thpo/mice was calculated
(see Experimental Procedures). In agreement with pheno-
typic data, LT-HSCswere further reduced at 1 year of age,
where limiting dilution experiments demonstrated a 157-
fold reduction of competitive repopulating units (CRUs)
in Thpo/ mice (Figure 2E). Thus, phenotypic as well as
functional evaluation of HSC numbers demonstrated an
age-progressive reduction of HSCs in Thpo/mice (sum-
marized in Figure S1B).
Previous studies have demonstrated that young adult
(up to 12 week old) Thpo/ and Mpl/ mice, although
having reduced levels of progenitors of multiple lineages,
sustain normal levels of mature myeloid cells with excep-
tion of the megakaryocyte lineage (de Sauvage et al.,
1996; Gurney et al., 1994). Notably, in the PB and BM of
1-year-old Thpo/ mice, we could demonstrate a slight
but significant reduction in the frequency of mature cells
of the short-lived granulocyte lineage (MAC1+; Figure 2F).
Because BM cellularity also became significantly reduced
in Thpo/ mice at this age (Figure 2A), the absolute re-
duction in BM MAC1+ myeloid cells was more extensive.
These results implicate that the severe reduction in HSCs
in Thpo/mice at 1 year of age results in a BM multiline-
age deficiency, in agreement with what is observed in
CAMT patients, typically a few years after birth (Ballmaier
et al., 2003).
Enhanced Cycling of HSCs in Thpo/ Mice
The cellular and possible molecular mechanisms by which
THPO ensures postnatal and adult HSC maintenance and
expansion while not affecting fetal HSC expansion were
next explored. We first performed a series of genetic ex-
periments to investigate whether regulation of the HSC
compartment by THPOmight involve suppression of apo-
ptosis, as it has been shown to be a potent in vitro survival
factor for highly enriched HSCs (Borge et al., 1996). First,
we demonstrated that THPO potently promotes in vitro
survival of functionally defined LT-HSCs (see Figures
S3A–S3D). Next, we intercrossed Thpo/ mice with
transgenic mice in which the potent antiapoptotic regula-
tor BCL2 is expressed under control of the H2K promoter,
resulting in high pan-hematopoietic (including HSC)
expression (Domen et al., 1998). Importantly, these mice
have previously been used to implicate permissive actions
of multiple cytokines through BCL2-mediated rescue of
the hematopoietic phenotype of cytokine-deficient mice
(Akashi et al., 1997; Lagasse andWeissman, 1997;Maras-Cell Skovsky et al., 1997). However, in the case of the LT-HSC,
ST-HSC, andMPPphenotypes of Thpo/mice, introduc-
tion of BCL2 had little or no effect (Figures 3A and 3B), fail-
ing to support a major involvement of antiapoptotic path-
ways in THPO-mediated regulation of postnatal HSCs.
Based on an initial screening by global (affymetrix-
based) gene profiling of LSKCD34FLT3 LT-HSCs and
LSKCD34+FLT3 ST-HSCs, purified from adult BM of WT
and Thpo/mice, we observed only small changes in the
expression of some key apoptotic regulators and in genes
implicated as regulators of self-renewal such as Bmi1,
Hif1a, ATM, and Tal1 (H.Q., R.M., and S.E.W.J., unpub-
lished data). Although most cell-cycle regulators, includ-
ing also the CDK inhibitors, showed little or no change in
expression, p57Kip2 was downregulated as much as 6-
to 7-fold in LSKCD34FLT3 LT-HSCs and 2- to 3-fold
in LSKCD34+FLT3 ST-HSCs from Thpo/ BM (H.Q.,
S.E.W.J., unpublished data). The downregulation of
p57Kip2 in LSKFLT3 cells was confirmed by quantitative
real-time-PCR (Q-PCR) (Figure 4A), and also expression
of the CDK inhibitor p19INK4D (Tschan et al., 1999)
was somewhat reduced, whereas p21Cip1, p27Kip1, and
p18INK4C were not significantly affected (Figure 4A).
Reduced p57Kip2 expression was observed in
LSKCD34FLT3 LT-HSCs as well as LSKCD34+FLT3
ST-HSCs (Figure 4B). Notably, we found p57Kip2 to be
selectively expressed in LSKCD34FLT3 LT-HSCs,
whereas the CDK inhibitors p21Cip1 and p27Kip1 impli-
cated in HSC and progenitor regulation (Cheng et al.,
2000a; Cheng et al., 2000b), showed more comparable
expression levels in LT-HSCs, ST-HSCs, and MPPs
(Figure 4C).
As several Hox transcription factors have been impli-
cated as potent promoters of HSC self-renewal (Anton-
chuk et al., 2002; Lawrence et al., 2005; Sauvageau
et al., 2004), we here investigatedwhether their expression
was potentially altered in Thpo/ HSCs. Notably, the ex-
pression levels of Hoxb4, Hoxa5, Hoxa9, and Hoxa10
were all reduced (2.1- to 4.3-fold) in Thpo/ LSKFLT3
cells (Figure 4D) with a preferential reduction in the most
primitive LSKCD34FLT3 cells (Figure 4E).
Based on the downregulation of the CDK inhibitor
p57Kip2, we next investigated the potential requirement
of THPO in regulation of quiescent HSCs. In support of
such a role, we found accelerated bromodeoxyuridine
(BrdU) incorporation kinetics in cells enriched for HSCs
in Thpo/ mice (Figures 5A and 5B). In keeping with
this, reduced numbers of Thpo/ LSK cells were in the
quiescent G0 state, and increased numbers were in G1
and S/G2/M (Figures 5C and 5D). The same pattern of
reduced quiescence and enhanced cycling was seen in
LSKCD34FLT3 and LSKCD34+FLT3 cells (Figure 5E).
Furthermore, we also found a markedly reduced fraction
of Thpo/ LSK and LSKCD34FLT3 cells with a side(E) CRUs (±95% confidence intervals) in WT and Thpo/ BM, as calculated for two femurs and two tibias from five 1-year-old mice. For each ge-
notype, cells at different doses (104, 2 3 104, 5 3 104 of WT cells/mouse, and 8 3 104, 2 3 105, 5 3 105 Thpo/ cells/mouse) were transplanted
into 16–20 recipients.
(F) Mean (±SD) percentages of myeloid (MAC1+) cells in PB and BM of 1-year-old Thpo/ mice (n = 4–6 mice/group).tem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 675
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THPO Maintains Quiescent HSCsFigure 3. Forced Expression of hBCL2 Fails to Correct the HSC Deficiency in Thpo/ Mice
(A) Representative FACS analysis of LSK subsets in BM from 11- to 14-week-old WT, Thpo/, H2k-hBCL2, and Thpo/H2k-hBCL2mice (n = 4–7).
Mean percentages of total BM cells in each subpopulation are shown.
(B) Absolute numbers of LSKCD34FLT3 LT-HSCs (left) and LSKCD34+FLT3ST-HSCs (right) per BM (two femurs and two tibias) in 11- to 14-week-
old WT, Thpo/, H2k-hBCL2, or Thpo/H2k-hBCL2 mice (n = 4–7 each). Numbers represent fold reduction in LT-HSCs, ST-HSCs, and MPPs in
Thpo/ mice. When comparing the LSKCD34FLT3 cells in Thpo/ mice, the reduction was not significantly different (p = 0.14) on a WT and
H2k-hBCL2 background.population (SP) phenotype (Figure 5F). Specifically, a
41-fold reduction in the number of LSKCD34FLT3 SP
(2.4% of WT counterparts) was observed (Figure 5G),
a phenotype proposed to be tightly coupled to quiescent
HSCs (Arai et al., 2004). Thus, THPO promotes postnatal
maintenance of quiescent HSCs.
Role of THPO in Posttransplantation HSC
Expansion
Unlike in steady-state adult BM, where HSCs are mostly
quiescent or slowly cycling (Bradford et al., 1997; Chesh-
ier et al., 1999), HSCs transplanted into myeloablated
recipients are stimulated to expand and rapidly replenish
HSCs and downstream progenitor cells (Pawliuk et al.,
1996). In a typical experimental BM transplantation set-
ting, only a small fraction of the normal HSC compartment
is transplanted, resulting in an initial rapid cycling and
expansion phase, followed by reestablishment of steady
state where HSCs re-enter a quiescent or slow cycling
status (Pawliuk et al., 1996). Thus, we hypothesized that
the dynamic posttransplantation expansion of HSCs
might also be deficient in Thpo/ recipients. To investi-
gate this, we transplanted 4 3 103 WT BM LSK cells into
myeloablatedWT or Thpo/ recipient mice (experimental
design, see Figure S4). In agreement with previous studies
(Fox et al., 2002), the survival of Thpo/ recipients was676 Cell Stem Cell 1, 671–684, December 2007 ª2007 Elsevierreduced to only 43% (6 out of 14), whereas all WT recipi-
ents survived, and this correlated with a dramatic throm-
bocytopenia in Thpo/ recipients (Figure 6A). Despite
the high number of LSK cells transplanted, total donor-
derived blood cell reconstitution, as well as myeloid and
B cell lineage reconstitution, was significantly reduced in
Thpo/ recipients after 16 weeks (Figure 6B). Moreover,
donor-derived LSK stem cells as well as LINSCA1KIThi
myeloid progenitors were reduced 6.1- and 4.6-fold, re-
spectively, in primary Thpo/ compared toWT recipients
(Figures 6C and 6D). Most notably, when BM cells from
Thpo/ primary recipients were transplanted into sec-
ondary myeloablated Thpo/ recipients, the hematopoi-
etic defect became evenmore severe (Figures 6E and 6F),
andmore than 50%of Thpo/ recipients died by 8 weeks
posttransplantation, whereas all WT recipients survived
(see Figures S5A and S5B). Total BM cellularity was
reduced as much as 3-fold (Figure 6E), donor-derived
LSK stem cells were undetectable, and LINSCA1KIThi
myeloid progenitors also almost completely depleted in
the surviving secondary Thpo/ recipients already 8
weeks posttransplantation (Figures 6F and 6G). Thus,
THPO plays a critical role in HSC maintenance in steady
state as well as in regenerating adult BM.
Although the long-term reconstitution experiments de-
scribed above established a critical role of THPO inInc.
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THPO Maintains Quiescent HSCsFigure 4. Transcriptional Expression of CDK Inhibitors and Hox Transcription Factors in Thpo/ LSK Subsets
(A) Quantitative PCR expression analysis of p57Kip2, p19INK4D, p21Cip1, p27Kip1, and p18INK4C in LSKFLT3 cells from WT and Thpo/ mice.
(B) Expression of p57Kip2 in Thpo/ LSKCD34FLT3 and LSKCD34+FLT3 cells (mean ± SD).
(C) Expression of p21Cip1, p27Kip1, and p57Kip2 in WT LSK subsets. Data are mean (±SD) values from two independent experiments. nd, not detect-
able.
(D) Expression of Hoxb4, Hoxa5, Hoxa9, and Hoxa10 in LSKFLT3 cells fromWT and Thpo/mice. Data represent mean (±SEM) values of triplicate
determinations from two independent experiments.
(E) Expression of Hoxb4, Hoxa5, Hoxa9, and Hoxa10 in LSK subsets from WT and Thpo/ mice. Data represent mean values from one to two
independent experiments. All results (A–E) are shown relative to hprt expression levels.replenishment and/or maintenance of HSCs posttrans-
plantation, they could not separate between a role of
THPO in maintenance of HSCs in the BM after trans-
planted HSCs go back into steady-state cycling and/orCell Sduring the extensive HSC expansion that occurs in the
initial phase after transplantation in ablated recipients
(Pawliuk et al., 1996). In fact, as THPO proved to not be
required for fetal HSC expansion, it appeared likely thattem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 677
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THPO Maintains Quiescent HSCsFigure 5. THPO Regulates Quiescent HSCs
(A) Analysis of BM SCA1hiKIThi cells from WT and Thpo/ mice exposed to BrdU for 3 days. Panels show gating strategy of SCA1hiKIThi cells (top)
being BrdU+ (low). The numbers in the profiles show percentages of BrdU+SCA1hiKIThi cells.
(B) Percentages of BrdU+SCA1hiKIThi cells in 14-week-old WT and Thpo/ mice. Data are from two separate experiments (n = 12 mice of each
genotype).
(C–E) Cell-cycle analysis of Thpo/ LSK cells. Data are from one of two independent experiments with similar results (three mice of each genotype in
each experiment). Cell-cycle status within defined LSK subsets (LSKCD34FLT3, LSKCD34+FLT3) was determined by simultaneous two-param-
eter analysis with DNA content versus KI-67 expression. (C) Numbers in quadrants show the percentage of gated LSK cells in each of the cell-cycle
phases (G0, G1, and S/G2/M). (D) Mean cell-cycle distribution of total LSK cells from one representative experiment. (E) Mean cell-cycle distribution of
LSKCD34FLT3 (left) and LSKCD34+FLT3 (right) cells from one representative experiment.
(F and G) Proportion and numbers of BM LSK subsets in 9-week-old WT and Thpo/mice with SP phenotypes. (F) Representative FACS profiles of
SP andMP analysis in whole BM (WBM), total LSK, and LSKCD34FLT3 cells in WT and Thpo/mice. The numbers in the panels show percentage
of SP/percentage of MP out of total nucleated cells. (G) Numbers of gated LSK and LSKCD34FLT3 (n = 3 of each genotype) with SP phenotype in
BM (two femurs and two tibias). Each dot represents a single mouse. Horizontal bars show mean numbers of SP cells within LSK and LSK
CD34FLT3 cells. Also shown are p values comparing WT and Thpo/ mice.THPO might also not be required for the initial phase of
HSC expansion posttransplantation. To specifically inves-
tigate this, we next analyzed the reconstitution of BM LSK
and LSKFLT3 cells at 3 and 6 weeks after transplantation678 Cell Stem Cell 1, 671–684, December 2007 ª2007 Elsevieof WT LSK cells in WT and Thpo/ recipients. Notably,
reconstitution of total LSK as well as LSKFLT3 cells
was severely impaired after 3 as well as 6 weeks post-
transplantation (Figure 7), in agreement with THPOplayingr Inc.
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Myeloablated WT or Thpo/ mice (CD45.2) were transplanted with 4 3 103 purified WT LSK (CD45.1) from 10- to 12-week-old mice. PB reconsti-
tution was analyzed at 16 weeks after primary transplantation.
(A) Survival curves (left) and platelets (right) in transplanted mice.
(B) Total PB donor cells (CD45.1) and donor-derived myeloid, B, and T cells. Horizontal bars show the mean values.
(C) Representative FACS plots of LINSCA1+KIThi (LS+K) and LINSCA1KIThi (LSK) analysis in WT and Thpo/ recipient mice 17 weeks after
transplantation. Numbers shown are mean percentages relative to total BM cells (n = 6–14).
(D) Total donor-derived BM LS+K cells (left) and LSK cells per femur and tibia in WT and Thpo/ recipients 17 weeks after transplantation. Each dot
represents a single recipient, and bars show mean cell numbers per both femurs and tibias. Data are from two independent experiments.
(E) Total BM cells in Thpo/ and WT secondary recipients at 8 weeks after transplantation.
(F) Representative FACS plots for LS+K and LSK analysis in Thpo/ and WT secondary recipients 8 weeks after transplantation. Numbers shown
are mean percentages of LS+K and LSK cells of total BM cells in all recipients of each group (n = 3–7).
(G) Total donor-derived LS+K and LSK cells in Thpo/ and WT recipients 8 weeks after transplantation. Each dot represents single recipients, and
bars show mean values from two femurs and tibias.a critical role in promoting HSC expansion early in post-
transplantation.
DISCUSSION
The importance of the classical hematopoietin family of
cytokines as key regulators of blood lineage development
has been recognized for decades, and their utility trans-
lated into clinical medicine (Kaushansky, 2006). It was
also early appreciated that many of these cytokines,Cell Stwhen acting in synergy with ligands for receptors of the
cytokine tyrosine kinase (FLT3 and KIT) and gp130 (IL-6
and IL-11) families, could potently promote the prolifera-
tion of primitive progenitors and stem cells (Lyman and
Jacobsen, 1998; Metcalf, 1993; Ogawa, 1993). Thus, it
was expected that hematopoietin cytokines would also
play important physiological roles in HSC regulation, but
providing evidence for this as well as translating their po-
tent synergistic activities into a means to ex vivo expand
HSCs has proven to be a daunting task (Oostendorpem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 679
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transplantation Is THPO Dependent
Myeloablated WT or Thpo/ mice (CD45.2)
were transplanted with 4 3 103 purified WT
LSK (CD45.1) from 10- to 12-week-old mice.
(A) Representative donor-derived (CD45.1)
LSK and LSKFLT3 analysis inWT and Thpo/
recipient mice 3 weeks after transplantation.
Numbers shown are mean percentages rela-
tive to total BM cells (n = 7–8).
(B) Total donor-derived BM LSK (left) and
LSKFLT3 (right) cells per two femurs and
tibias in WT and Thpo/ recipients 3 and 6
weeks after transplantation. Each dot repre-
sents a single recipient, and bars show mean
cell numbers per both femurs and tibias. Data
are from two independent experiments.et al., 1999; Sorrentino, 2004). However, more recent ob-
servations have suggested that THPO, initially identified
as the primary regulator of megakaryocyte and platelet
formation (Kaushansky, 1995), might also be involved
in regulation of HSCs (Buza-Vidas et al., 2006; Fox et al.,
2002; Kimura et al., 1998; Solar et al., 1998). Although
initially having been identified through in vitro studies as
a survival factor (Borge et al., 1996) and a synergistic factor
for HSC proliferation (Sitnicka et al., 1996), efforts to pro-
mote HSC expansion with cytokine combinations includ-
ing THPO proved to only marginally improve HSC mainte-
nance (Bryder and Jacobsen, 2000; Ema et al., 2000).
In the present studies, we establish through comple-
mentary phenotypic and functional analysis a key role of
THPO and MPL in regulation of HSC maintenance in
steady-state adult BM and through cell-cycle analysis
provide findings suggesting that a key physiological role
of THPO in promoting maintenance of adult HSCs might
be to suppress or prolong their cell-cycle transit, and
thereby protect the steady-state HSC compartment from
premature exhaustion. In contrast, we show that the ex-
tensive HSC expansion that occurs in the fetal liver (Paw-
liuk et al., 1996) is THPO independent, and in fact, analysis
of Thpo/ as well as Mpl/ mice demonstrated that FL
HSCs were slightly expanded. The contrasting findings680 Cell Stem Cell 1, 671–684, December 2007 ª2007 Elsevierin FL and adult steady-state BM could be compatible
with THPO and MPL playing a distinct role in regulation
of quiescent or slowly cycling HSCs, but not in regulation
of rapidly expanding HSCs. However, as THPO also
proved to be of considerable importance for short-term
expansion of HSCs after transplantation into lethally irradi-
ated recipients (Pawliuk et al., 1996), as well as during the
first few weeks postnatally when HSCs continue to cycle
(Bowie et al., 2006), our findings are more compatible
with a distinct role of THPO inmaintenance and expansion
of HSCs in postnatal and adult hematopoiesis, but not
during fetal development. Themechanism bywhich THPO
is critically involved in promoting HSC expansion after
transplantation remains to be established, although it ap-
pears likely that it also might be to prolong cell-cycle tran-
sit, as rapidly cycling HSCs have recently also been shown
to have a protracted cell-cycle transit when compared to
downstream progenitors (Dykstra et al., 2006; Nygren
et al., 2006).
Although we cannot exclude a potential role of THPO
also in homing of HSCs after transplantation, the reduced
HSC numbers in Thpo/ mice established through limit-
ing dilution experiments could not be entirely due to a
homing defect of Thpo/ HSCs, because phenotypic
analysis of the HSC compartment in Thpo/ miceInc.
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sive postnatal loss of HSCs in steady-state Thpo/
mice. Furthermore, in the limiting dilution experiments,
Thpo/ BM cells were intentionally transplanted into
WT recipients along with WT competitor cells, providing
a source of normal THPO expression and function in the
transplant as well as in the recipient microenvironment.
In agreement with a distinct role of THPO in sustain-
ing quiescent HSCs in steady-state adult BM,
LSKCD34FLT3 cells in Thpo/BMhad clearly acceler-
ated cell-cycle kinetics. Most notably, we found the CDK
inhibitor p57Kip2 to be clearly downregulated in Thpo/
LSKFLT3 cells. Although the role of p57Kip2 in HSC regu-
lation has not been established, it has, in agreement with
our studies, recently been reported to be preferentially
expressed in LT-HSCs (Yamazaki et al., 2006). Notably,
in the accompanying paper by Yoshihara et al. (2007) in
this issue of Cell Stem Cell, in vivo administration of MPL
blocking antibodies resulted in a similar reduction in
p57Kip2 expression in HSCs as we observed in Thpo/
mice. An important role of THPO in promoting HSC main-
tenance and expansion was further supported by reduced
expression in Thpo/ LSKFLT3 cells of several Hox
genes proposed to promote HSC self-renewal (Antonchuk
et al., 2002; Lawrence et al., 2005; Sauvageau et al.,
2004), including Hoxb4, Hoxa5, Hoxa9, and Hoxa10.
The finding of altered transcriptional expression of CDK
inhibitors and Hox transcription factors provides insight
into potential mechanisms of action for how THPO might
promote in vivo HSCmaintenance and expansion, but fur-
ther studies will be needed to establish whether these ob-
servations represent more than an association. This could
be a considerable challenge, as the expression of several
of these genes appears to be downregulated in Thpo/
HSCs and because considerable redundancy has been
proposed among these regulators. With regard to the
downregulated expression of Hox genes in Thpo/
LSKFLT3, it is of interest that THPO has been shown to
promote nuclear transport of Hoxa9 in primitive hemato-
poietic cells (Kirito et al., 2004).
Although the clear association of the enhanced cycling
with downregulation of p57Kip2 and p19INK4D in Thpo/
HSCs implicated that THPO regulates HSC cell-cycle qui-
escence, an alternative scenario would be that THPO
would simply promote survival of high MPL expressing
quiescent HSCs (Borge et al., 1996; Buza-Vidas et al.,
2006). However, whereas overexpression of BCL2 has
been used to successfully demonstrate the permissive ac-
tions of other cytokine functions in hematopoiesis (Akashi
et al., 1997; Cross and Dexter, 1991; Lagasse and Weiss-
man, 1997; Maraskovsky et al., 1997), introduction of high
levels of BCL2 failed to rescue the HSC deficiency in
Thpo/ mice. Importantly, although these findings failed
to support a role of antiapoptotic pathways in mediating
the effects of THPO on HSC maintenance, they do not
preclude involvement of antiapoptotic regulators distinct
from BCL2.
Ample evidence suggests that HSC quiescence is spe-
cifically regulated and secured in anatomically andmolec-Cell Sularly defined stem cell niches in the BM (Calvi et al., 2003;
Zhang et al., 2003). In agreement with this, the only previ-
ously identified extrinsic regulator of HSC quiescence,
angiopoietin-1, has been demonstrated to be expressed
by osteoblasts in the BM niche (Arai et al., 2004) and is
exclusively important for regulation of postnatal HSCs
(Puri and Bernstein, 2003). Although THPO is primarily
produced in the liver, BM stroma cells express Thpo (Dor-
mady et al., 2001), and in the accompanying paper from
Yoshihara et al. (2007), THPO is demonstrated to be
expressed in osteoblasts in the BM stem cell niche.
They also demonstrate through transitory gain and lack-
of-function approaches in adult mice that THPO promotes
HSC quiescence and maintains HSC interactions with
their niche components, in agreement with our finding of
accelerated cell cycling of HSCs in Thpo/ mice. In light
of these findings, it is a possible scenario that the
enhanced cycling of HSCs in Thpo/mice might be sec-
ondary to their egress out of the stem cell niche, which
might result in release from their quiescent state in the
niche.
Upon BM transplantation of ablated recipients, adult
HSCs undergo extensive self-renewal divisions to expand
the number of HSCs and to replenish progenitors of mul-
tiple lineages (Iscove and Nawa, 1997; Pawliuk et al.,
1996). Herein we demonstrate that this dynamic process
is perturbed in Thpo/ mice, resulting in reduced HSC
expansion in the short term after transplantation and
eventually in a complete exhaustion of HSCs in the
absence of THPO.
The importance of THPO and MPL in human HSC regu-
lation has been implicated in patients with CAMT with
lack-of-function mutations in Mpl (Ballmaier et al., 2003).
Although the HSC compartment has not been studied
directly in these patients, they might have an identical
HSC phenotype as here reported for Thpo/ mice. As
for mice, THPO might not be critically involved in regula-
tion of human fetal HSCs, as all CAMT patients are born
with a pure megakaryocyte/platelet deficiency and an
otherwise normocellular BM (Ballmaier et al., 2003). How-
ever, during the course of CAMT, most patients develop
a progressive multilineage BM failure, in support of a criti-
cal role of THPO in regulation of postnatal human HSC
maintenance, but not fetal HSC expansion.
In conclusion, our studies establish a unique role of
THPO in postnatal HSC expansion and maintenance of
quiescent HSCs in the adult BM.
EXPERIMENTAL PROCEDURES
Mice
Congenic CD45.1 and CD45.2 C57BL/6 WT mice were used as con-
trols and as transplant recipients. Thpo/ (CD45.1 or CD45.2) mice
have been described (de Sauvage et al., 1996) and were kindly pro-
vided by Dr. John W. Adamson, (Blood Center of Southeastern Wis-
conson). Mpl/ mice were generated as described (Alexander et al.,
1996). H2k-hBCL2 mice (Domen et al., 1998) were kindly provided
by Dr. Albrecht Muller, Wuertzburg, Germany. The H2k promoter en-
sures high pan-hematopoietic levels of human BCL2, including
HSCs (Domen et al., 1998). Both strains had been backcrossed totem Cell 1, 671–684, December 2007 ª2007 Elsevier Inc. 681
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approved by the animal ethical committees at Lund University and the
Walter and Eliza Hall Institute.
PB Cell Analysis
PB was counted in an automated cell counter (Sysmex) and prepared
for fluorescence-activated cell sorting (FACS) analysis as previously
described (Yang et al., 2005).
FACS of HSC Subsets
BM cellularities were calculated by using the total number of cells
collected from two femurs and two tibias after crushing in a mortar
(Thpo/ mice) or flushing (Mpl/ mice). FLs were obtained from
time-matched pregnant WT and Thpo/ or Mpl/ mice at E14.5,
where the time of the vaginal plugwas set as E0.5.Modifications of pre-
viously described procedures were used to evaluate the distribution or
to sort cells within the LSK compartment (Adolfsson et al., 2005; Yang
et al., 2005). Briefly, FL or BM cells from 2-week-old mice were incu-
bated with lineage (LIN)-cocktail (purified rat antibodies against
B220, CD5, CD8a, GR-1, TER-119, plus CD4 and MAC1 in BM only).
Subsequently, the cells were stained with goat anti-rat–tricolor, anti-
mouse-FLT3-PE, -SCA1-FITC/SCA1-Pacific blue/SCA1-PE-CY5.5, -
KIT-APC/KIT-APC-Alexa 750, or isotype-matched control antibodies.
BM cells from adult mice were then stained with anti-mouse-CD34-bi-
otin, in addition to FLT3 or CD150, SCA1, KIT, and subsequently with
SAv-PE-Cy7. All samples were stained with the vital marker Fluorogold
or 7-amino actinomycin (7-AAD; Sigma-AldrichCo.) prior to analysis on
FACSCalibur or FACSDiva (BD). Data analysis was carried out with
FlowJo software (TreeStar Inc.). The purities of all LSK subsets were
reproducibly higher than 99%. For specific details regarding antibodies
used for FACS see the Supplemental Experimental Procedures.
SP Analysis
To evaluate the distribution of SP andmain population (MP) cells within
the LSKCD34FLT3 compartment, unfractionated BM cells were
suspended at 1 million cells/ml and stained with 2.5 mg/ml Hoechst
33342 (Invitrogen, Molecular Probes) followed by cell surface stainings
and analysis on a FACSDiva as previously described (Nadin et al.,
2003; Yang et al., 2005). The gatings of SP andMPwere based on neg-
ative controls in which Verapamil (100 mM) (ABBOT Scandinavia) was
used when cells were incubated with Hoechst 33342.
Competitive Repopulation Assay
The competitive reconstitution assay using the congenic CD45.1/
CD45.2 mouse model has been described previously (Yang et al.,
2005). Briefly, different doses of CD45.1 or CD45.2 donor BM or FL
cells were injected intravenously along with 2 3 105 competitor
CD45.1 or CD45.2 BMcells intomyeloablated (900 cGy) CD45.1 hosts.
PB was analyzed at 3 and 16 weeks after transplantation for donor re-
constitution by FACS. Briefly, nucleated blood cells were stained with
antibodies against CD45.1, CD45.2, MAC1, B220, CD4, and CD8a.
Positively reconstituted mice were defined as having a minimum of
0.1% CD45.2+ total cells and 0.02% CD45.2+ cells of each of the my-
eloid (MAC1+), B (B220+), and T (CD4/CD8+) lineages after analysis of
a minimum of 53 104 PB cells (Buza-Vidas et al., 2006). The specificity
of the FACS staining is controlled by analyzing PB of untransplanted
CD45.1 mice with the same anti-CD45.2 and lineage antibodies,
always finding a background CD45.2 staining of less than 0.01% of
total PB cells and less than 0.002% of CD45.2+MAC1+ cells. When
multiple limiting dilution transplant doses were used, and CRUs were
calculated based on the frequencies of positive mice at each dose
(Szilvassy et al., 1990), using Limit Dilution Analysis software (StemCell
Technologies, Inc.). In experimentswhere a single low dose of BMcells
was used, the frequency of repopulating cells was calculated based on
the formula p = 1  10^ (log [frequency of negative mice]/cell dose)
(Buza-Vidas et al., 2006).682 Cell Stem Cell 1, 671–684, December 2007 ª2007 ElsevierNoncompetitive Repopulation Assay
Briefly, 4 3 103 sorted WT BM LSK cells (CD45.2) were injected intra-
venously into myeloablated (900 cGy) WT or Thpo/ CD45.1 hosts.
PB at 3, 6, and 16 weeks after transplantation was analyzed for donor
BM LSK and PB lineage reconstitution by FACS as described above.
BrdU and Cell-Cycle Status Analysis of HSCs
Age-matched WT and Thpo/ mice (12 weeks old) were given an
intraperitoneal injection with 1 mg BrdU (Sigma-Aldrich) per 6 g
body weight and allowed to freely drink water containing BrdU
(1 mg / ml) for 72 hr prior to isolation of BM cells for analysis. Cells
were stained with lineage markers, rat anti-mouse-SCA1-PECy5.5
(eBioscience), -KIT-APC, -FLT3-PE, -CD34-biotin, and subsequently
with SAv-PE-Cy7. BrdU incorporation was evaluated by using a BrdU
and 7-AAD intracellular staining kit (BD PharMingen). Cell-cycle sta-
tus within defined LSK subsets (LSKCD34FLT3, LSKCD34+FLT3,
and LSKCD34+FLT3+) was determined by simultaneous two-param-
eter analysis using DNA content versus KI-67. KI-67 expression was
detected with anti-KI-67-FITC (BD PharMingen), and DNA was
stained with Hoechst 33342 (Sigma, 2.5 mg/ml).
Q-PCR
RNA extraction and Q-PCR of adult BM LSKCD34FLT3,
LSKCD34+FLT3, and LSKCD34+FLT3+ cells or LSKFLT3 cells were
performed as previously described (Adolfsson et al., 2005; Ma˚nsson
et al., 2007). For specific TaqMan Assays-on-Demand probes used,
see the Supplemental Experimental Procedures. The assay was per-
formed on an ABI 7900 Fast Real-Time PCR System with TaqMan
Fast Universal PCR master mixture (Applied Biosystems). Data were
analyzed by 7900 Fast System SDS Software 2.2.1. All experiments
were performed in triplicates, and differences in cDNA input were com-
pensated for by normalization against Hprt expression levels.
Statistics
Data are expressed as mean (±SD or ±SEM). Unless otherwise stated,
the statistical significance of differences between WT and Thpo/
mice was determined by using the two-tailed Mann-Whitney t test or
an unpaired t test.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and five figures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/1/6/671/DC1/.
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